Additionally, several clinical trials are exploring the effectiveness of DNase I nebulized inhalation to reduce lung symptoms in patients with respiratory distress syndrome (NCT03368092) or COVID-19 (NCT04541979, NCT04402970, NCT04387786, NCT04359654). This evidence concerns the gene DNASE1 and COVID-19.